Zhonghong Pulin Medical Products Co. Ltd. (300981) Fair Value & Analysis

Healthcare · CN · Market cap 4.6B CNY

Below-average quality, and screening another 64% overvalued on our models.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case (¥6.62). The favourable scenario is already priced in.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range ¥7.57 – ¥41.50 · fair‑value band ¥3.85 – ¥6.62 · the ¥14.73 price screens above the ¥5.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Zhonghong Pulin Medical Products Co. Ltd. (300981) currently trades at ¥14.73, while our model-based Fair Value estimate is ¥5.24, implying the stock looks roughly 64.4% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Zhonghong Pulin Medical Products Co. Ltd. generated revenue of 2.3B CNY at a net margin of -5.4%. Revenue declined 4.3% year over year. It earns a return on equity of -2.4%. Net debt stands at 133M CNY. Fundamentals as of Aug 13, 2026

Our scenario range runs from ¥3.85 (bear case) to ¥6.62 (bull case); at ¥14.73, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high and 41% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at -64%, 300981 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based (¥8.22) versus Multiples (¥7.85). Highest evidence: EV/EBITDA (54).

Key figures & financial health

Quality Score breakdown

About the company

Zhonghong Pulin Medical Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of disposable health products for medical and industrial use in China and internationally. It operates in three segments: Health Protection Division; Safety Infusion Division; and Innovation Incubation Division.

Full company description

Zhonghong Pulin Medical Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of disposable health products for medical and industrial use in China and internationally. It operates in three segments: Health Protection Division; Safety Infusion Division; and Innovation Incubation Division. The Health Protection Division offers nitrile gloves, PVC gloves, natural latex gloves, radiation-proof gloves, polyisoprene gloves, examination findom, and condoms, as well as various other disposable exam, surgical, and protective gloves. Its Safety Infusion Division provides infusion equipment-related products, such as precision infusion sets, indwelling needles, common infusion sets, common syringes, and blood collection tubes, etc. The Innovation Incubation Division offers infusion and syringe pumps, infusion information collection systems, disposable non-invasive EEG electrodes, disposable medical temperature sensors, non-invasive blood pressure cuffs, and radial artery compression tourniquets, as well as closed loop temperature management systems, and disposable atomizers. It also provides wireless continuous monitoring sensors and probes; and engages in scientific research and technical services. The company exports its products to approximately 80 countries and regions. Zhonghong Pulin Medical Products Co., Ltd. was founded in 2010 and is based in Tangshan, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Zhonghong Pulin Medical Products Co. Ltd. reported revenue of ¥2.4B in FY2025 versus ¥4.9B in FY2021, a compound −16.6%/yr. Reported net income was −¥112M in FY2025.

300981 screens 64% overvalued. Compare with Intuitive Surgical, Inc →

Peer Group

Medical Instruments & Supplies · 205 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.